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CObjective: To consider the methods available to model Alzheimer’s
disease (AD) progression over time to inform on the structure and de-
velopment of model-based evaluations, and the future direction of
modelling methods in AD. Methods: A systematic search of the health
are literature was undertaken to identify methods to model disease
rogression in AD. Modelling methods are presented in a descriptive
eview. Results: The literature search identified 42 studies presenting
ethods or applications of methods to model AD progression over time.
he review identified 10 general modelling frameworks available to em-
irically model the progression of AD as part of a model-based evaluation.
even of these general models are statistical models predicting progres-
ion of AD using a measure of cognitive function. The main concerns with
odels are on model structure, around the limited characterization ofisease progression, and on the use of a limited number of health states to O
ealth
2 4S
al So
doi:10.1016/j.jval.2010.12.008apture events related to disease progression over time. None of the avail-
ble models have been able to present a comprehensive model of the
atural history of AD. Conclusions: Although helpful, there are serious
imitations in the methods available to model progression of AD over
ime. Advances are needed to better model the progression of AD and
he effects of the disease on peoples’ lives. Recent evidence supports
he need for a multivariable approach to the modelling of AD progres-
ion, and indicates that a latent variable analytic approach to charac-
erising AD progression is a promising avenue for advances in the sta-
istical development of modelling methods.
eywords: Alzheimer’s disease, cost-effectiveness analysis, health
echnology assessment, modelling methods.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Alzheimer’s disease (AD) is the most common cause of dementia.
It is a chronic progressive neurodegenerative condition that rep-
resents an increasingly significant health care burden on individ-
uals and health care systems [1]. Decision makers are faced with
challenging questions about the development of health care ser-
vices, and also over the funding of future research in the area of
AD. These issues demand an understanding of the social and eco-
nomic influence of AD on people’s lives, and an understanding of
the effects of health care interventions.
Providing a greater understanding on these areas can be sup-
ported, in part, through the use of economic and statistical meth-
ods available to model the progression, influence, and costs asso-
ciated with AD over time [2–4]. Modelling methods have been used
for many years to improve our understanding of a large number of
health conditions, and to inform decision making. For example,
modelling methods have been used in a variety of ways and set-
tings to predict the risk of future cardiovascular events, based on
known patient-level characteristics [5,6].
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Published by Elsevier Inc.The development of methods to model AD over time has
been relatively slow, compared to similar research for condi-
tions such as cancer, diabetes, and cardiovascular disease, even
though the influence of AD and the size of the population af-
fected by AD are very large. It seems that the advances in drug
therapies for AD signalled the arrival of modelling methods to
support claims for the cost-effectiveness of treatment; for ex-
ample, cholinesterase inhibitors. Modelling studies have used a
simplified representation of the underlying disease and symp-
tom structure for AD, and there are limitations in the methods
used to date to structure models for AD [7–9].
Given the growing impact of AD, and the ongoing development
of new therapeutic strategies and interventions, it is important to
consider the broader evidence base on the methods available to
model AD over time. Previous reviews [7,9,10] have specifically
discussed the use of decision-analytic models in AD. These are
often cost-effectiveness analyses that synthesize the evidence
from a number of different sources to compare alternative strate-
gies (e.g., treatment options). This review reports on the current
methods available to model disease progression in AD, specifically
Economics, Health Economics Group, Peninsula Medical School,
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ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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622 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 2 1 – 6 3 0on the methods available to structure models, and the statistical
methods and empirical data, upon which these decision-analytic
models, often referred to as model-based evaluations [11], are
based.
Modelling methods and the place of model structure
Determining model structure is central to the development of
model-based evaluations that seek to address specific questions
(e.g., Are cholinesterase inhibitors cost-effective?). Model struc-
ture should usually be determined by considering the relationship
between the inputs (natural history of disease, treatment path-
ways, epidemiologic data, effectiveness data, health state values,
and costs) and the resultant information output that is required by
the decision maker (e.g., number of health events, outcomes, and
summary of cost-effectiveness) [11]. Brennan et al. [11] have pro-
vided a detailed and clear taxonomy of model structures for use in
model-based evaluations, as in the economic evaluation of health
technologies, covering decision trees, Markov models, cohort
models, individual level modelling methods, and methods cover-
ing both discrete and continuous time modelling.
The issue of model structure has been relatively neglected in the
guidance published on the development of decision-analytic models,
with this issue often limited to simple outline and summary infor-
mation. Sculpher et al. [12] have advised that model structure should
be as simple as possible, consistent with the stated decision problem,
and a theory of the disease, and not defined by data availability. This
is helpful advice, but may be seen as somewhat inconsistent with
other elements of guidance, where it is accepted that data availability
may affect development and choices around model structure [13,14].
In practice models are often developed around those data that are
available to model the natural history of a disease. For example, by
those analysts making submissions (manufacturers or independent
assessment teams) to the UK National Institute of Health and Clinical
Excellence (e.g., Loveman et al. [15]). When making choices over
model structure there may be a number of practical considerations
that shape how a model is developed. It is important that the choice
of model structure is based on an understanding of the health care
system, the available evidence, and the knowledge and judgment of
the analyst on which model structures are available and appropriate
in which circumstances [11]. Other practical considerations are fac-
tors such as the amount of time and level of resources available to
develop a model.
Whilst there are many considerations in developing the overall
structure of a model-based evaluation, Brennan et al. [11] have
drawn attention to an important prior consideration in model de-
velopment, whereby “the choice of [health] states and risk factors,
and the identification of their relationship to each other should
normally precede the choice of model structure [more generally]”
[11]. For example, determining the statistical modelling of disease
activity and progression. This key consideration draws attention
to the stages of model development, and it is a particularly impor-
tant consideration where models need to be developed relatively
quickly using secondary evidence. Cohen and Neumann [9] cap-
tured this important prior consideration in their review of AD
models, through the distinction they make between empirical
and/or mechanistic models versus decision-analytic models [9].
They define empirical and mechanistic models, as a form of pre-
model analyses, with these models being used to describe rela-
tionships between predictive factors and outcomes, for example
statistical models using regression equations derived from obser-
vational or clinical epidemiologic studies [9]. These references to
empirical and mechanistic components of model structure (i.e.,
statistical relationships) highlight important and distinct stages of
model development, with the prior considerations on model
structure (referred to by Brennan et al. [11]) being distinct from the
broader specification of the structure and framework for model-
based evaluations.Following from these considerations, it is clear that there is a
need to balance the ability of a model to represent (describe) the
natural history of a condition (e.g., treatment pathway), with the
pragmatic consideration of being able to put a model together.
Empirical and mechanistic components, such as statistical models
of disease progression driven by risk factors, are a central consid-
eration in determining the feasibility of model development, out-
side of the more general structural considerations related to a
particular evaluation (e.g., model cycle length, time horizon to be
used and Markov model vs. continuous modelling approaches).
Without such an empirical basis upon which to model disease
progression (e.g., outcomes and events) it will not be possible to
undertake analyses other than in a hypothetical context, which
will have limited policy relevance.
Reviews of decision-analytic models in AD have highlighted
the importance of the empirical and mechanistic components of a
decision model (e.g., published risk equations and survival analy-
ses), but they have not provided detail on these important struc-
tural components of decision models. It is on this basis that our
review investigates the statistical methods available to model dis-
ease progression in AD, and how these methods have been used,
or could be used, in model-based evaluations in AD.
Methods
Literature search
A systematic search of the health care literature was undertaken to
identify methods to model disease progression in AD. The search
strategy (Appendix 1 found at doi:10.1016/j.jval.2010.12.008) was de-
veloped with input from an Information Specialist. Electronic data-
bases were searched, applying the search strategy to MEDLINE and
EMBASE, with search terms then adapted as necessary for searches
in the Cochrane Library, PsychINFO, HTA Database, NHS EED, CEA
Registry, and EconLit database. The search was limited to studies
published in English, covering literature up to March 2010. Refer-
ences identified were reviewed by two authors (CG and JS) to identify
relevant articles.
Studies were included if they reported on the use of a model to
consider the progression of AD over time. These included statistical
models, for example, those that developed predictive risk equations
based on observational or epidemiologic data, and decision-analytic
models that had been used to address specific questions or to model
costs and/or consequences over time. Economic evaluations con-
ducted alongside clinical trials were excluded unless they also mod-
elled aspects of AD progression over time. Resulting reference lists
and citations in retrieved articles were further checked to ensure that
no eligible studies had been missed. Existing reviews [7,9,10] were
lso examined to identify relevant studies. The identified modelling
tudies are summarized, the approaches available to model disease
rogression over time are discussed in a summary descriptive re-
iew, and the review points to recommendations for the future di-
ection of modelling of AD.
Results
The literature search identified 42 studies presenting methods, or
applications of methods, used to model AD progression over time
(summary characteristics of the identified studies are presented in
Appendix 2 found at doi:10.1016/j.jval.2010.12.008). Most studies
used Markov models (n  27 out of 42) and a cohort modelling
framework (n  29 out of 42) to characterize disease progression.
The majority of the identified studies (n  25 out of 42) used mea-
sures of cognition (cognitive scores) alone to model AD progres-
sion. The review identified 10 modelling approaches that are con-
sidered to be general modelling frameworks (Table 1), either being
Table 1 – Summary characteristics of the identified Alzheimer’s disease (AD) progression models.
Model (label, reference) Health outcomes/events Analytical/statistical
approach
Risk factors, determinants
of disease progression
Baseline data source(s) Baseline sample
characteristics
(summary)
Applications, related
evaluations
Fenn & Gray model
Fenn & Gray, 1999 [49]
Time in stages of AD
severity (defined using
MMSE: mild to moderate,
moderate to severe).
Survival analysis, using
an accelerated
failure-time model
(with Weibull
distribution, hazard
function).
Cognitive scores - MMSE
(adjusted for age, and
baseline MMSE)
Placebo groups from two
RCTs (n  235, n  239)
followed up over 26
wks.
Mean age
74.8/72
AD severity, mild
0.45/0.41;
moderate 0.55/
0.57
Hauber et al. [52]
Hauber et al. [53]
CERAD-MMSE model
Mendiondo et al., 2000 [29]
Time in specific MMSE
score; rate of decline in
cognitive functioning
(mean time associated
with one point change in
MMSE).
Regression analysis
using time-index
method, using
average MMSE scores
between time
intervals of  180 d
apart.
Cognitive scores -MMSE A subset of a prospective
US longitudinal study
of AD progression
(CERAD) followed up
between 6 mo and 7 y
(mean 2.3 y). N  719
Mean age 71.9
AD Severity not
stated
Small et al. [30]
CERAD-CDR model
Neumann et al., 2001 [18]
Time in stages of AD
severity (defined using
CDR); mortality.
Markov cohort model
to characterise
progression of AD
through disease
stages defined by
CDR (severity);
transit probabilities,
between AD stages,
estimated using a
Cox proportional
hazards model.
Estimation of quality
adjusted life years.
Cognitive functioning (CDR)
adjusted for sex, age,
behavior, duration in
severity stage
Consortium to Establish a
Registry in Alzheimer’s
Disease (CERAD) a
prospective US
longitudinal study of
AD progression
recruited 1986-1995 and
followed up annually
for up to 8 y (mean not
stated). n  1,145
45% age 75 y
AD Severity, mild
0.52; moderate
0.39.
López-Bastida et al. [23]
Fuh & Wang [22]
Kirbach et al. [21]
Martikainen et al. [25]
Kulasingam et al. [26]
McMahon et al. [28]
Ikeda et al. [24]
McMahon et al. [27]
Neumann et al. [20]
Kungsholmen-MMSE
model
Jönsson et al, 1999 [54]
Time in disease stages
defined by MMSE;
mortality.
Markov model with
transit probabilities
Cognitive function (MMSE) A subset of a Swedish
prospective
longitudinal study of
the elderly
(Kungsholmen Project)
recruited 1987-1992
with single follow up
(mean  3.32 years). n
 206
All aged75 y.
AD severity, mild
0.20; moderate
0.21; moderate-
severe 0.20;
severe 0.38.
Teipel et al. [56]
Wimo et al. [69]
AHEAD model
Caro et al., 2001 [31]
Time in pre-full time care,
full time care, mortality.
Markov model with
time dependent
hazard functions.
Age, age at AD onset, duration
of AD, EPS, psychotic
symptoms, cognitive
functioning (modified
MMSE).
US prospective
longitudinal study to
examine AD
progression (Y Stern et
al., 1997) [32] followed
up semiannually for up
to 7 y (mean not
stated). n  236
Mean age 73.1
AD Severity Mild
(All)
Getsios et al. [34]
Green et al. [35]
Caro et al. [36]
Ward et al. [37]
Migliaccio et al. [38]
Garfield et al. [39]
Caro et al. [40]
Getsios et al. [33]
(continued on next page)
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Table 1 (continued)
Model (label, reference) Health outcomes/events Analytical/statistical
approach
Risk factors, determinants
of disease progression
Baseline data source(s) Baseline sample
characteristics
(summary)
Applications, related
evaluations
McDonnell model
McDonnell et al, 2001 [16]
MMSE change, care setting
change, mortality
Two regression models
were used to
estimate changes in
MMSE, care setting
and death
Random-effects, linear
regression model;
estimated baseline
MMSE and change in
MMSE over time.
Cognitive functioning (MMSE)
adjusted for age, sex,
baseline MMSE, education,
time in study.
Dutch prospective
longitudinal study to
examine chronic disease,
disability in the elderly
(Rotterdam Study)
recruited 1990-
1993 (mean follow-up
3.4 y).
Baseline AD diagnosis n 
306
New (incident) AD
diagnoses n  95
Mean age 84.9
AD Severity at first
interview after
onset: minimal
0.173/0.242;
mild 0.399/0.60;
moderate 0.314/
0.147; severe
0.114/0.011.
N/A
Kinosian model
Kinosian et al., 2000 [17]
Survival, time in
institutional care, level of
dependency, costs of
care.
Markov cohort model,
analysis using grade
of membership
(statistical)
techniques.
Multiple risk factors (n  72)
including age, sex,
residence, ADL/cognitive
(SPMQS) impairment and
behavioral problems were
evaluated simultaneously
US National Long Term
Care Survey, sample of
US Medicaid
beneficiaries recruited
1984-1994. n 3254
69% age  75 y
Suspected AD
Severity not stated
N/A
CERAD-SIB model
Weycker et al., 2007 [57]
Time in disease (severity)
stages defined by SIB (SIB
mapped to MMSE, CDR).
Nursing home placement
conditional on cognitive
functioning.
Regression analysis
was used to predict
monthly change in
SIB score based on
current SIB score.
Cognitive functioning (SIB) US validation study of SIB
in moderate-severe AD
(Schmitt et al. [58])
followed up
semiannually for 1
year. n  180
Mean age 72.1
AD severity
mild 0.23
moderate 0.7
severe 0.07
N/A
Memantine model
Jones et al., 2004 [41]
Time to dependency,
institutionalisation and
death
Markov model with
transit probabilities
for disease severity
estimated from the
placebo group in a
clinical trial and
from observational
data. Transit
probabilities for
dependency,
mortality and care
setting based on
observational data.
Cognitive functioning (MMSE),
dependency [conditional on
MMSE/severity], care
setting [conditional on
MMSE/severity].
Subset of a UK
observational study of a
qualitative classification
of AD patients by
dependency (LASER-AD).
(Livingston et al. [43])
followed up for 6 mo. n
95
Subset of placebo arm of
RCT (Reisberg et al., [42])
followed for 28 wks. n
103
Age not stated
AD severity,
moderate-
severe 0.31;
severe 0.69.
Mean age 76
AD severity,
moderate-
severe 0.41;
severe 0.59.
Gagnon et al. [44]
Antonanzas et al. [45]
Jönsson et al. [46]
François et al. [47]
Predictors ADAS-cog
model
Stern et al 1994 [59]
Mean 1-y change in ADAS-
cog.
Multiple regression
analysis of the
relationship between
the annual rate of
change and baseline
ADAS-cog score.
Cognitive functioning
(ADAS-Cog)
US prospective
longitudinal study to
examine AD
progression (RG Stern
et al. [59] followed for
mean 35 mo
N  111
Mean age 68.2
AD severity
distribution not
stated (mean
score
35.1  3.8).
Wattmo et al. [61]
Fagnani et al. [62]
RCT, randomized controlled trial; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; EPS, Extrapyramidial symptoms; SIB, Severe Impairment Battery; ADAS-Cog, Alzheimer’s
Disease Assessment Scale Cognitive Subscale; SPMQS, Short Portable Mental Status Questionnaire; N/A, Not applicable.
624
V
A
L
U
E
IN
H
E
A
L
T
H
1
4
(2
0
1
1
)
6
2
1
–
6
3
0
g
t
s
t
n
g
d
t
l
t
A
(
(
t
T
o
a
l
i
(
a
w
q
s
A
n
c
d
s
h
p
a
t
c
p
b
b
m
M
e
M
w
g
t
c
M
m
a
625V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 2 1 – 6 3 0modelling frameworks applied in a number of different settings,
often with some context-specific amendments, or studies that are
not specific to a particular policy question (e.g., not about effec-
tiveness or cost-effectiveness of an intervention), but could be ap-
plied in such a way. Thirty-eight of the 42 studies identified are
based on these 10 general models of AD progression. These gen-
eral models each present a different method to model the statis-
tical relationship between risk factors and health states (out-
comes). Table 1 presents the summary characteristics of these
general models showing the majority of models based on regres-
sion analyses, with predictive risk equations derived from obser-
vational data on AD.
Summary description of general (or generalizable),
approaches to the modelling of AD progression
The McDonnell model
McDonnell et al. [16] modelled AD progression using regression-
based statistical methods applied to patient-level data on cogni-
tive function (Mini Mental State Examination [MMSE] scores), care
setting, and mortality. The model predicts baseline MMSE and
subsequent change in MMSE score over time, using a random-
effects linear regression model, with covariates for age, sex, edu-
cation, and time. It is a model of MMSE progression over time, with
stages of the modelling specific to both earlier and later stages of
AD. The model was derived from data on a cohort of 306 prevalent
and 95 incident AD patients, identified in a prospective Dutch ob-
servational study of chronic illness and disability in the elderly,
with 3-year follow-up (1990–1993). The model predicted a decline
of 1.71 points in MMSE at 6-month intervals for incident cases of
AD, and a 0.91 point 6-month decline in prevalent cases of AD. The
findings from this linear MMSE model present different rates of
MMSE change against age groups, sex, and education. To comple-
ment the AD progression model (MMSE progression), McDonnell et
al. [16] presented a statistical model to predict the probability of a
change in place of residence and the probability of death. The
modelling approach was applied in an evaluative study to esti-
mate the progression of AD over time, in a comparative analysis of
two modelled cohorts of patients; patients treated with a cognitive
enhancer (a hypothetical intervention in their presentation), and
in untreated AD patients.
The Kinosian model
Kinosian et al. [17] modelled AD progression over time using re-
ression based methods and latent structure modelling, to explore
he relationship between multiple health indicators, and unob-
ervable constructs of health such as AD progression. Those au-
hors used a statistical modelling framework, similar to tech-
iques of factor analysis and latent class analysis, referred to as a
rade of membership technique, to explore patient-level data
rawn from 3254 elderly (aged 65 years and older) Medicare pa-
ients in a US National Long Term Care Survey, recruited and fol-
owed between 1982 and 1994. The statistical modelling was used
o estimate the care requirements in elderly people with possible
D, and to estimate costs associated with AD over the longer term
using a 10-year time horizon). Modelling identified health states
that could be used in a decision-analytic modelling framework)
hrough simultaneously evaluating multiple variables in the data.
he health states reflect profiles of AD, across six areas, with four
f these based on symptoms of AD (cognitive impairment, basic
ctivities of daily living (BADL), instrumental activities of daily
iving [IADL], behavior), and two contextual (whether or not living
n institutional care and level of health care costs). Health states
profiles) were used, with empirical data, to allocate patients
cross the disease health states, to model the proportion of people
ith AD spread across the health states over time, and the subse-uent transitions between health states over time. In this way the
tatistical methods provided a basis for estimating the nature of
D progression and subsequent costs. The data published by Ki-
osian et al. [17] provides a matrix that categorizes AD by age, sex,
ognitive impairment, and activities of daily living at baseline with
ata on prediction of survival, time spent in an institution, time
pent with a high degree of dependence (BADL 2), total costs and
ours of care, for each profile (AD health state) or broad set of
atients.
The Consortium to Establish a Registry in Alzheimer’s
Disease-Clinical Dementia Rating (CERAD-CDR) model
Neumann et al. [18] modelled AD over time using a state transition
Markov model (we refer to the CERAD-CDR model) to characterize
AD progression through stages of disease severity (cognitive func-
tion) and residential settings. In summary, the CERAD-CDR model
was based on annual transition probabilities, derived from the
CERAD database. The CERAD database included 1145 people with
AD, followed up to 8 years, with AD (severity) categorized as mild,
moderate, or severe AD, based on the CDR scale, a global measure
of patient functioning. Although the CDR could be described as an
aggregate indicator reflecting both cognitive and functional per-
formance, across six domains, the rating of each domain is based
exclusively on cognitive ability [19]. Therefore, the CERAD-CDR
model essentially relies on cognitive functioning to characterize
AD progression. A survival analysis approach was used to derive
transition probabilities between different stages of AD severity
(mild, moderate, and severe), for transition to a nursing home
setting and for the probability of death. The transition probabili-
ties derived from the CERAD data covered staging of AD severity
independent of residential setting, but the probabilities for resi-
dential setting (community or nursing home), and death were con-
ditional on disease severity, with higher probabilities as disease
severity progressed. The CERAD-CDR model transit probabilities
are derived to adjust for age, sex, the presence of high or low levels
of behavioral symptoms, and time spent in disease stage. The
CERAD approach has been one of the most widely used of all the
models and has been used to examine the effects of medications
[18,20–24], behavioral interventions [25], and screening technolo-
gies [26–28] on disease progression in AD.
The CERAD-MMSE model
Mendiondo et al. [29] also used the CERAD database to present an
lternative approach for the modelling of AD progression over
ime. These authors present a mathematical representation of de-
line in MMSE over time, providing a rate of change in MMSE
oints per year, with decline dependent on average MMSE score
etween the time intervals examined. Analyses and modelling are
ased on MMSE scores from 719 people followed between 6
onths and 7 years (mean follow-up 2 years). In the modelling,
MSE values declined in a non-linear fashion, and a quadratic
quation was applied to estimate the time to progress from one
MSE score to a lower MMSE score. Using regression analysis, age
as found to be a significant factor (with younger patients pro-
ressing more rapidly), education was a marginally significant fac-
or and sex was not significant in declines in MMSE. Floor and
eiling effects were noted, which might limit the sensitivity of the
MSE-based model to changes in early and late stage disease. The
ethods developed by Mendiondo have been applied in an evalu-
tion by Small et al. [30].
The Assessment of Health Economics in Alzheimer’s Disease
(AHEAD) model
Caro et al. [31] present a model of AD progression, the AHEAD
model, which has been widely used (at times in an adapted form)
in cost-effectiveness analyses. The model has been presented in
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626 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 2 1 – 6 3 0detail elsewhere [31] and discussed in reviews of modelling meth-
ods for AD [7,15]. In summary, the AHEAD model is based on the
oncept of the need for full-time care (FTC) as a significant event in
he progression of AD, with FTC defined as a consistent require-
ent for care and supervision for the greater part of a day, regard-
ess of setting. The statistical modelling uses regression-based
echniques to derive predictive risk equations (or hazard func-
ions) for the likelihood of patients to require FTC, and to death.
he risk equations are a function of patient characteristics at a
ingle point in time with subsequent risks modelled over time. The
isk equation for FTC includes age, presence of extrapyramidial
ymptoms, presence of psychotic symptoms, cognition measured
y a modified MMSE, sex, age at disease onset, and duration of AD.
he risk equation for death includes inputs for the presence of
xtrapyramidial symptoms, duration of AD, sex, and cognitive
unction. The AHEAD model is based on the statistical analyses
resented by Stern et al. [32], where risk equations for requiring
the equivalent of nursing home placement (Caro et al. [31] refer to
FTC) and death are presented as a function of patient characteris-
tics, using Cox proportional hazard models. Thereafter, Caro et al.
[31] introduce the element of time-dependency to present risk
equations with time as a continuous variable. The original analy-
ses presented by Stern et al. [32] are based on data from a prospec-
ive US cohort study of 236 patients (probable AD and mild demen-
ia at the first assessment) followed semiannually for up to 7 years.
The AHEAD model has been used in numerous decision-ana-
ytic models, structured as Markov models using health states for
re-FTC, FTC, and death [31,33–40], with the AHEAD risk equa-
ions, either one or both, being used to model disease progression
etween these three health states over time (often over 5–10 years)
n comparisons between different cohorts of participants.
The memantine model
Jones et al. [41] modelled disease progression in moderately severe
to severe AD. The model, referred to here as the memantine
model, was developed to assess the cost effectiveness of meman-
tine, a neuroprotective agent/drug that aims to preserve func-
tional ability in more severely affected patients. The memantine
model is a Markov model with 13 health states (including death)
defined using severity level (moderate [MMSE score  14], moder-
ately severe [MMSE score 10–14), and severe [MMSE score 10]),
hysical dependency level (independent or dependent), and care
etting (institution or community). The model uses transition
robabilities between health states, applying a 6-month model
ycle over a 2-year time frame, and it is used to estimate time to
ependency, and time to institutionalization.
Health states in the memantine model are described in a mul-
ivariate way, but transition probabilities between the health
tates are estimated using a domain specific framework (i.e., by
everity, dependency, and care setting), with transitions between
tates calculated in a multiplicative manner; that is, by multiply-
ng the respective transition probability for severity by the proba-
ility for dependency and the probability for care setting. Transi-
ion probabilities were based on disease severity (MMSE) at the
eginning of each model cycle, with subsequent transitions for
ependency and care setting being secondary to disease severity.
he transition probabilities for AD severity are derived from pla-
ebo group data in a clinical trial [42]. Dependency transition prob-
bilities are derived from the same clinical trial for more severe
isease stages, and from a UK epidemiologic study [43] for moder-
ate disease stages. Probabilities for care setting were based on data
from both the UK cohort study [43] and a resource use study con-
ducted alongside the randomized controlled trial [42]. When in an
institutional care setting people remain in that setting. Mortality
probabilities, as a function of disease severity using the MMSE,
were taken from the cohort study.Jones et al. [41] applied this baseline model of AD progression to
evaluate the effects of memantine compared to placebo (controls),
adjusting transition probabilities in the memantine-treated co-
hort using randomized controlled trial data [42]. There have been
other applications of the memantine model [41,44–47] and its ap-
plication in cost-effectiveness analyses is discussed in some detail
by Kirby et al. [48].
The Fenn and Gray model
Fenn and Gray [49] modelled AD progression using statistical
methods (survival analysis techniques) to estimate the time to
event data for changes in cognitive scores (MMSE), and to predict
the subsequent time taken for people to move from one level of AD
severity to the next, with severity based on cognitive functioning
(MMSE). The model used three health states defined using MMSE
scores: mild (21–30), moderate (11–20), and severe (10). The
model estimated the time (measured in days) patients are likely to
remain at their current disease stage, depending on their age and
baseline MMSE score. Mortality was not considered in the model.
Analysis was based on patient-level data from two 26-week clini-
cal trials of rivastigmine [50,51], and hazard functions were de-
rived for movement between MMSE-defined health states. These
hazard functions were used in a Markov-type model to estimate
the progression of AD over time, and subsequent costs and out-
comes, in people treated with a cholinesterase inhibitor (rivastig-
mine) compared to those treated with placebo [49]. Differences are
estimated through the use of separate survival analyses and haz-
ard functions, based on different profiles of cognitive function (in-
formed by trial findings). There have been two other applications
of the Fenn and Gray methodology [52,53].
The Kungsholmen-MMSE model
Jönsson et al. [54] modelled AD progression through estimation of
transition probabilities between four AD health states defined us-
ing cognitive (MMSE) scores (mild 30–24, mild-moderate 23–18,
moderate 17–10, and severe 9–0), plus risk of death in each of
these health states. Progression (transition probabilities) was es-
timated based on analysis of epidemiologic data on 206 partici-
pants drawn from a Swedish cohort in a prospective longitudinal
study, the Kungsholmen Project, a study of disease costs in el-
derly patients aged 75 years or older. In this subset from the
study cohort the average time between baseline and the fol-
low-up assessment was 3.32 0.59 years). The 1-year transition
probabilities between AD severity (stage-stage) and death were
calculated based on the average time between baseline and the
follow-up assessment, and reflect an assumed constant linear
relationship. The Kungsholmen-MMSE model (health states and
transit probabilities) has been applied in three published eval-
uations [55,56,69].
The CERAD-Severe Impairment Battery (CERAD-SIB) model
Weycker et al. [57] modelled AD progression, in moderate-to-se-
vere AD, using a statistical model to predict change in cognitive
function over time, using the SIB. The predicted level of cognitive
function (SIB) was used, with data from the CERAD model [18], to
redict the risk of nursing home placement over time. In this way,
pplying a two-stage approach, the model presented by Weycker
t al. [57] estimates the monthly risk of nursing home placement,
onditional on predicted SIB scores. These authors argue that the
IB was more sensitive to changes in cognitive functioning in peo-
le with more severe AD because it permits more impaired pa-
ients to use nonverbal responses such as gestures or pointing to
nswer questions. The statistical model, predicting change in SIB,
as based on data drawn from a US validation study of the SIB in
80 moderate-severe (MMSE score 21) AD patients followed over
12 months [58]. SIB scores were mapped to MMSE or CDR severity
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Weycker et al. [57] apply the baseline model for SIB with CERAD
ata to assess the cost-effectiveness of memantine used with
onepezil versus donepezil alone, introducing a number of as-
umptions and data inputs in a decision-analytic model [57].
The Predictors Alzheimer’s Disease Assessment
Scale-Cognitive Function (ADAS-cog) model
Stern et al. [59] modelled AD progression, using a mathematical
odel to predict changes in cognitive function (ADAS-cog score)
ver time. The approach, similar to that taken by Mendiondo et al.
29], found a quadratic (nonlinear) relationship between ADAS-cog
nd AD severity, finding deterioration of cognitive function slower
n the mild and very severe stages of AD, compared to people with
oderate AD. Statistical analyses were based on data from a sub-
et of participants in an early prospective study of the natural
istory of AD [60], with Stern et al. [59] using a cohort of 111 pa-
ients selected where data were available on repeated observa-
ions of cognitive performance (ADAS-cog) and at least two assess-
ents at an interval of at least 12 months. Data used had a mean
ollow-up of 35 months (range 12–90 months), with analyses rely-
ng solely on cognitive function as a measure/predictor of AD pro-
ression. The methods developed by Stern et al. [59] have been
pplied in AD progression models presented by Wattmo et al. [61]
nd Fagnani et al. [62].
Summary review of general approaches to the modelling of
AD progression
In the empirical and mechanistic modelling methods described
here, various mathematical approaches (e.g., transit probabilities,
hazard ratios, and regression equations and coefficients) were
used to model the progression of AD over time, across health
states and events such as death and institutionalization. A range
of endpoints and outcomes, and related economic effects, were
considered in the ten models described here. Eight models used
changes in disease severity, measured as transitions between dis-
ease severity stages (i.e., memantine model [41], Fenn and Gray
model [49], CERAD-CDR model [18], Kungsholmen-MMSE model
[54], and CERAD-SIB model [57]) or as changes in cognitive scale
scores (i.e., Predictors ADAS-cog model [59], CERAD-MMSE model
[29], and McDonnell model [16]), with all of these eight models
efining disease severity in terms of cognitive function. Five of the
0 models included placement in an institution, such as a nursing
ome or home for the elderly as an endpoint (CERAD-CDR model
18], McDonnell model [16], Kinosian model [17], CERAD-SIB model
[57], and memantine model [41]), although this has only been
modelled independently of cognitive function in two of these
models (Kinosian model [17] and McDonnell model [16]). Three
odels considered dependency or the need for full-time care, in-
ependent of care setting, as an element of the disease progres-
ion model (AHEAD model [31], Kinosian model [17], and meman-
ine model [41]), in one case being the only outcome of interest
AHEAD model [31]).
Six of the 10 models used relatively small data sets, between
11 and 306 participants, to undertake the statistical modelling
sed to inform disease progression (Predictors-ADAS-cog model
59], CERAD-SIB model [57], Kungsholmen-MMSE model [54],
AHEAD model [31], memantine model [41], and McDonnell model
[16]). Follow-up duration in the data used for statistical analyses
have also been variable across the modelling methods described,
with three of the 10 models using data from clinical studies with a
follow-up duration of only 26 weeks to 52 weeks (Fenn and Gray
model [49], memantine model [41], and CERAD-SIB model [57]).
Furthermore, in the remaining models, where follow-up data were
collected between 3 and 10 years, there was a high level of attrition
in the data, particularly beyond 3 years, which although reflectingthe nature of the condition also affects on the robustness of the
data. Another important feature, in the assessment of the statis-
tical robustness of the models, is that generalizability of the find-
ings from some of the statistical methods is limited due to the
characteristics of the participant data used for analyses. For ex-
ample, in two models (McDonnell model [16] and Kungsholmen-
MMSE model [54]) there are limitations in the generalizability of
data to an AD treatment-eligible population, with these studies
relying on data from participants with high levels of baseline dis-
ease severity, high rates of residential care, a mean age older than
age 85 years, and with mortality rates being particularly high (be-
tween 66% and 76%, over 3 years).
In only two of the models, the CERAD-CDR model [18] and the
CERAD-MMSE model [29], are analyses based on a relatively large
sample size with follow-up over a reasonable duration. In both of
these models a further strength is the quality of the standardized
clinical assessment methods that were used in the CERAD study
(cohort). On the other hand, both of these models describe disease
progression based on cognitive function alone.
Seven of the 10 general models described here are statistical
models of cognitive function over time, reporting findings from
regression-based analyses of datasets for cognitive scores re-
ported using a range of measurement scales (e.g., MMSE, ADAS-
cog, CDR, and SIB). This approach does not reflect a coherent theory
of the natural history of AD, and introduces limitations in the mod-
elling methods. It is increasingly accepted that cognition is not a good
predictor of disease progression in AD, and that reliance on cognition
ignores the independent affect of functioning and behavior on health
care needs and costs [63–66]. Although some models have attempted
to incorporate variables other than cognition when modelling dis-
ease progression (i.e., AHEAD model [31], memantine model [41], and
Kinosian model [17]), none of the available models have been able to
capture/present a comprehensive model of the natural history of AD,
given the importance of functional ability, and behavior and mood,
on the characterization of AD progression.
Discussion
The evidence base available to analysts and decision makers wish-
ing to carry out evidence syntheses through development of mod-
els is largely restricted to the 10 general models introduced here.
These general (statistical) models represent the opportunities
available to structure model-based evaluations, providing an em-
pirical and mechanistic framework to relate risk factors to health
states and outcomes that are policy relevant and relevant to peo-
ple with AD. When weighing up the merits of each of the ap-
proaches available, judgments are needed on the rigor and appro-
priateness of the alternative modelling methods, for specific
applications and evaluations.
Published guidance on good practice in decision-analytic mod-
elling is helpful in the assessment of modelling methods for spe-
cific evaluations [13,14], drawing attention to key considerations.
The current methods available for modelling AD progression offer
useful insights, but all have limitations. The main concerns, raised
in previous reviews [7,9], are on model structure, around the lim-
ited characterization of disease progression through use of a nar-
row description of the natural history of AD, and on the use of a
limited number of health states to capture events related to dis-
ease progression over time. A more general concern is against the
data inputs used, which reflect a limited evidence base available to
inform on important model inputs related to health care costs,
health state values, and mortality across AD stages. Such limita-
tions in the methods available should not prevent the develop-
ment of a modelling framework (evaluation of a decision problem),
yet highlights the importance of being transparent with assump-
tions, and the limitations in the modelling methods and the evi-
dence available [13,14].
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tunity to develop a model that will be helpful in informing a deci-
sion and the characteristics of the model (e.g., model structure,
data inputs, and level of uncertainty and consistency). However,
previous reviews have not drawn specific attention to the empir-
ical and mechanistic elements of model structure, as presented in
this review. On these, specific consideration is required to assess
the robustness and generalizability of the statistical relationships
informing on disease progression, linking risk factors to events
and/or health outcomes. This area of assessment has been char-
acterized as ‘prior data modelling’ or ‘pre-model analyses’, in the
methodologic guidance on modelling methods [13,14], and assess-
ment of models in this area is important.
Although a detailed critical review of modelling methods is not
presented here, this summary review highlights the need for an-
alysts, reviewers, and decision makers to be aware of the trade-
offs between considerations relevant for determining the struc-
ture of a decision-analytic model, and the importance of the
statistical analyses upon which decision-analytic models are
based. These trade-offs and considerations around model struc-
ture, as well as those more relevant to the broader requirements of
model-based evaluations, will often be context specific (to the de-
cision-making perspective and evaluation setting), and the use of
published guidance on good practice for decision-analytic model-
ling [13,14], by both analysts and others, is recommended to in-
form debate when weighing up the value of a model and the po-
tential relevance of its findings.
Advances need to be made in the methods available to model
disease progression in AD [7,9], yet there are challenges for those
wishing to provide robust methods to model the progression of
AD. Clinical trials in AD have not provided long-term outcome
data relevant to the modelling of disease progression, and relevant
to economic evaluations. Epidemiologic research in AD has not
placed a focus on modelling disease progression to inform health
policy. There are challenges in using short-term clinical trial out-
comes—such as changes in cognition, neuropsychiatric symp-
toms, or activities of daily living—often assessed in trials using a
range of different instruments, to predict longer-term outcomes
such as the need for FTC, time to institutionalization, mortality,
onset of severe AD, and quality-adjusted life-years.
Although the current modelling methods do provide some as-
sistance to those wishing to develop a better understanding of AD,
and on the effectiveness and cost-effectiveness of treatments, it
will be important in future years to develop new methods that take
a less narrow view of AD, the effects of AD on peoples’ lives, and
the influence of health technologies on the experience of AD. Re-
cent contributions to the AD literature, exploring the underlying
symptom structure for AD, have provided both support for the
view that cognitive function (cognitive scores) alone is not a good
way to model AD progression, and insights on a more comprehen-
sive approach to the modelling of AD progression [67,68].
Tractenberg et al. [67] modelled the underlying structure of
ymptoms in AD using data on mild-to-moderate AD from two
andomized controlled trials. They used latent variable analyses
o explore the relationships between multiple types of health in-
icators and unobservable variables or construct that drive dete-
ioration in AD. The analyses are based around the three main
ymptom domains of AD, covering cognition, function, and behav-
or, and findings support the proposition that a single symptom
odel (e.g., cognition alone) is a poor conceptualization of AD.
urthermore, analyses suggest that although an intervention may
mprove cognitive scores it can do so without altering the under-
ying disease process. Tractenberg et al. [67] present a more com-
rehensive conceptualized model of AD progression than seen to
ate, using the three symptom domains of cognition, behavior,
nd functioning as causal factors (referring to numerous methods
or the potential measurement of each of these), and also referringo the role of a general neurological latent variable (representing
or example synapse loss). The results are preliminary analyses
ased on a relatively small cross-section of AD patients enrolled in
linical trials, and they need to be extended to longitudinal data
efore the findings can more clearly inform on modelling of AD
rogression over time. The findings, however, point to potential
uture developments and to a more comprehensive approach to
odelling AD progression.
With the use of patient-level longitudinal data, the type of sta-
istical model suggested by Tractenberg et al. [67] may be able to
distinguish underlying disease progression from the symptom
structure of AD. To be practical any future developments would
need to be set out against a set of health states (outcomes), with
policy relevance, and would need to estimate path weights (or
model coefficients) as a means of predicting transition between
health states over time. It is possible to hypothesize on a potential
modelling framework, constrained (in the first instance) to consid-
eration of the symptom structure of AD, and with potential con-
straints on the number of possible health states (to present as
feasible and practicable). Figure 1 presents such a scenario, and
future statistical advances using longitudinal data on AD could
present a means of populating such a model with appropriate
data. The suggested model is not set out as the ideal, just a means
of improving on the methods currently available to model AD over
time, and to act as a spur for further debate.
Conclusions
This review draws attention to the modelling methods available to
empirically model the progression of AD, as a prior consideration
when developing the structure of a model-based evaluation. The
evidence base is sparse and undeveloped, and over recent years
there have not been major advances in the modelling methods
currently available. Although helpful, there are serious limitations
in the currently available modelling methods. It is widely ac-
knowledged that a single symptom, such as cognition, is not able
to characterize AD progression, and that AD is heterogeneous in
Fig. 1 – Schematic/structure for proposed modelling
structure for Alzheimer’s disease progression. Note: Health
states using three symptom domains, each at up to three
levels (state i to n; max 27 states); statistical methods
needed to predict probabilities of movement between
health states; and death as part of the model, but may be
informed by secondary/epidemiologic data.presentation and disease course; for example, across the main
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are needed to better model the progression of AD, and its affects
on peoples’ lives. The recent evidence suggests that future mod-
elling initiatives should incorporate a multivariable approach, and
that a latent variable analytic approach to characterizing AD pro-
gression is a promising avenue for advances in the statistical de-
velopment of modelling methods. The challenge is to apply these
statistical techniques with longitudinal data, and to transfer find-
ings into a relatively simple policy-relevant model that can be
employed to inform on the pragmatic concerns of both clinical and
health policy decision makers.
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